anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Transgenic nonhuman mammals (mice, rabbits, goat, sheep, pigs and cows) producing phosphorylated lysosomal proteins in their milk, and methods of generating the same are discussed.  Phosphorylation occurs at the 6' position of a mannose side chain residue.  Methods of purifying lysosomal proteins from milk and incorporating the proteins into pharmaceutical compositions for use in enzyme replacement therapy are also discussed.  The purified protein can then be mixed with a pharmaceutical carrier for intravenous, intradermal, intramuscular or oral administration. The transgene in the transgenic mammal comprises a mammary gland specific promoter, a mammary-gland specific enhancer, a secretory DNA segment encoding a signal peptide functional in mammary secretory cells, and a recombinant DNA segment encoding a lysosomal protein, usually an enzyme. The recombinant DNA segment is operably linked to the secretory DNA segment to form a secretory recombinant DNA segment. The secretory-recombinant DNA segment is in turn operably linked to the promoter and to the enhancer. The transgene, in an adult, is capable of expressing the secretory-recombinant DNA segment in the mammary secretory cells to produce a form of the lysosomal protein that is processed and secreted by the mammary secretory cells into milk as a mannose 6-phosphate containing lysosomal protein. The concentration of the mannose 6-phosphate containing lysosomal protein in the milk is usually at least 100 pg/ml.
Recombinant human immunodeficiency virus antigens capable of immunologically identifying the presence of early anti-HIV antibodies are stably expressed in a number of cell lines. These antigens have several clinically important applications as non-hazardous tools in the detection of human immunodeficiency virus exposure/infection, and in screening methods for HIV infection in idiopathic chronic lymphopenia (ICL). These techniques are improved over existing immunologically based and PCR based detection methods, as they provide for the detection of infection/exposure in samples determined to be negative by conventional forms of these types of assays that do not detect anti-HIV gp160 antibodies that react to conformational epitopes of HIV. The invention finds particular application in the detection of human immunodeficiency virus exposure/infection in infants. The earlier detection of the described methods is provided through the preserved immunoreactivity of the described recombinant conformationally intact human immunodeficiency virus that is capable of detecting a class of 'early' anti-human immunodeficiency virus antibody not previously detectable by standard Western Blot or ELISA methods. The human immunodeficiency virus gp160 envelope antigen comprises one of the specific recombinant antigens examined with clinical human samples in these improved screening methods.
Molecular oxygen is typically delivered to patients via oxygen inhalation or extracorporeal membrane oxygenation (ECMO), potentially resulting in systemic hyperoxia from liberal oxygen inhalation or localized hyperoxia in the lower body from peripheral venoarterial (VA) ECMO. Consequently, this exposes the gastrointestinal tract to excessive oxygen levels. Hyperoxia can trigger organ damage due to the overproduction of reactive oxygen species and is associated with increased mortality. The gut and gut microbiome play pivotal roles in critical illnesses and even small variations in oxygen levels can have a dramatic influence on the physiology and ecology of gut microbes. Here, we reviewed the emerging preclinical evidence which highlights how excessive inhaled oxygen can provoke diffuse villous damage, barrier dysfunction in the gut, and gut dysbiosis. The hallmark of this dysbiosis includes the expansion of oxygen-tolerant pathogens (e.g., Enterobacteriaceae) and the depletion of beneficial oxygen-intolerant microbes (e.g., Muribaculaceae). Furthermore, we discussed potential impact of oxygen on the gut in various underlying critical illnesses involving inspiratory oxygen and peripheral VA-ECMO. Currently, the available findings in this area are somewhat controversial, and a consensus has not yet to be reached. It appears that targeting near-physiological oxygenation levels may offer a means to avoid hyperoxia-induced gut injury and hypoxia-induced mesenteric ischemia. However, the optimal oxygenation target may vary depending on special clinical conditions, including acute hypoxia in adults and neonates, as well as particular patients undergoing gastrointestinal surgery or VA-ECMO support. Last, we outlined the current challenges and the need for future studies in this area. Insights into this vital ongoing research can assist clinicians in optimizing oxygenation for critically ill patients.
Lenalidomide maintenance given until disease progression. Long term follow-up 5 years post last patient randomized.
The present invention pertains to a system of collaborative modifiers that are assembled into a multi molecule complex  in vivo  within a cell using bioorthogonal chemical reactions. The system of the invention is composed of multiple binding molecules having a binding affinity to a biological target macromolecule. Each of the binding molecules individually can easily be delivered into a target cell and then, when they bind to their target in the cell, will assemble into a higher multi-molecule complex on the target to increase overall binding specificity, selectivity and strength. Using the invention allows to mimic complex protein-protein interactions, for example the binding of biological macromolecules such as antibodies or receptor ligands with a set of small binding molecules that can be irreversibly assembled during use. The invention is of particular use for therapeutic applications involving intracellular drug targets and/or for crossing the blood brain barrier for targets within the central nervous system and/or for improving therapeutics penetration in tumour tissue. Thus, invention further provides pharmaceutical compositions comprising the components of the system of the invention, and their use in therapy of various diseases. Also provided are methods for the manufacture and design of the collaborative system and system components of the invention.
All procedures will be performed by experienced endoscopists (\>3 years of experience/\>1000 polypectomies) with the patient in the left lateral position under propofol sedation.Using ERBE electrosurgical unit - EndoCut Q mode (effect interval duration) and forced coagulation mode in H-EMR group.The polyp size will be assessed by boston biopsy forceps (open jaws -7mm) or boston jumbo biopsy forceps (open jaws 10mm) or submucosal injection needle (Olympus (4mm)). A standard snare will be used.After polypectomy, the area is inspected for residual polyp using NBI and if present, will be resected using biopsy forceps.
It was planned to give "Enteral and Parenteral Nutrition Training" to the nurses in the experimental group, based on the literature. The content of the training guide was sent to ten experts in the field and content validity was made. Enteral and parenteral nutrition training was given face to face, in 15-20 minutes, using verbal presentation and written materials (brochures). "Descriptive Survey Form" was applied to the experimental group (n=35) at the beginning of the research. Other measurement tools, "Enteral and Parenteral Nutrition Care Knowledge Test" and "Care Behavior Scale-24 (BDI-24)" were administered three times: before the training, within one or two days of the training and three weeks after the training.
Risk Summary

Metronidazole is present in human milk at concentrations similar to maternal serum levels, and infant serum levels can be close to or comparable to infant therapeutic levels. There are no data on the effects of metronidazole on milk production. Animal studies have shown the potential for tumorigenicity after oral metronidazole was administered chronically to rats and mice [see Nonclinical Toxicology (13.1)]. This drug is not intended to be administered chronically; therefore, the clinical relevance of the findings of the animal studies is unclear. 

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LIKMEZ and any potential adverse effects on the breastfed infant from LIKMEZ or from the underlying maternal condition. Alternatively, a lactating woman may choose to pump and discard human milk for the duration of LIKMEZ therapy, and for 48 hours after the last dose and feed her infant stored human milk or formula.
Advance care planning is the process that allows individuals to express their future healthcare values and preferences so that these wishes can be enacted in the event that they become incapacitated and unable to participate in their own healthcare decisions. In the case of Alzheimer's disease or related dementia (ADRD), the person with dementia (care recipient), almost inevitably loses decisional capacity toward the end of life, given the progressive decline in cognitive functioning that accompanies the disease over time. The care partners to persons with dementia, most often family members such as spouse/partners and adult children, are therefore tasked with making end-of-life decisions on behalf of the care recipient with ADRD. These care partners are not always well-informed of the care recipient's end-of-life values and preferences and therefore may not feel confident in their ability to make decisions regarding care and treatment at the end-of-life, resulting in unnecessary, futile, and often unwanted medical treatments and interventions. Oftentimes, families do not want to engage in these challenging conversations and wait too long, whereby the care recipient with ADRD no longer has the decisional ability to participate in the advance care planning process. We developed "The LEAD Guide" (Life-Planning in Early Alzheimer's and other Dementias), as a tool to help persons with preclinical awareness of ADRD risk and those with early-stage cognitive impairment to begin these important conversations with a care partner. In this NIH Stage-1 behavioral intervention study we will refine the LEAD Intervention based on our pilot work (Stage 1A) and then evaluate the usability, acceptability, feasibility, and initial efficacy of the LEAD Intervention (Stage 1B). We will recruit a diverse sample of 60 community-dwelling ADRD pairs, defined as a care recipient in the preclinical or early stage of ADRD, plus their current or anticipated care partner (i.e., spouse/partner or adult child). Results are expected to show that the LEAD Intervention can improve outcomes related to decision-making self-efficacy through greater advance care planning congruence and improve subjective well-being, anxiety, and relationship quality as perceived and reported by both the care recipient and the care partner. Results from this study have the potential to guide and accelerate the implementation of the LEAD Intervention in community and healthcare practice, where a dementia-focused advance care process is needed.
Therapy is usually started with one 2.5 mg tablet of INVERSINE1 twice a day. This initial dosage should be modified by increments of one 2.5 mg tablet at intervals of not less than 2 days until the desired blood pressure response occurs (the criterion being a dosage just under that which causes signs of mild postural hypotension).

The average total daily dosage of INVERSINE1 is 25 mg, usually in three divided doses. However, as little as 2.5 mg daily may be sufficient to control hypertension in some patients. A range of two to four or even more doses may be required in severe cases when smooth control is difficult to obtain. In severe or urgent cases, larger increments at smaller intervals may be needed. Partial tolerance may develop in certain patients, requiring an increase in the daily dosage of INVERSINE1.

Administration of INVERSINE1 after meals may cause a more gradual absorption and smoother control of excessively high blood pressure. The timing of doses in relation to meals should be consistent. Since the blood pressure response to antihypertensive drugs is increased in the early morning, the larger dose should be given at noontime and perhaps in the evening. The morning dose, as a rule, should be relatively small and in some instances may even be omitted.

The initial regulation of dosage should be determined by blood pressure readings in the erect position at the time of maximal effect of the drug, as well as by other signs and symptoms of orthostatic hypotension.

The effective maintenance dosage should be regulated by blood pressure readings in the erect position and by limitation of dosage to that which causes slight faintness or dizziness in this position. If the patient or a relative can use a sphygmomanometer, instructions may be given to reduce or omit a dose if readings fall below a designated level or if faintness or lightheadedness occurs. However, no change should be instituted without the knowledge of the physician.

Close supervision and education of the patient, as well as critical adjustment of dosage, are essential to successful therapy. 

Other Antihypertensive Agents

When INVERSINE1 is given with other antihypertensive drugs, the dosage of these other agents, as well as that of INVERSINE1, should be reduced to avoid excessive hypotension. However, thiazides should be continued in their usual dosage, while that of INVERSINE1 is decreased by at least 50 percent.
This was a double-blinded prospective cohort study. The acupuncture needles were first separated into two groups. One group of needles was subjected to SCF-N treatment while the other was not. The needles were then randomly analyzed with scanning electron microscope and energy dispersive X-ray spectroscopy to ensure quality and minimize experimental error. For each participant, one hand was randomly assigned to the treatment group with SCF-N-treated acupuncture needles and the other hand was assigned to the control group with the stainless steel needles. The time interval between the acupuncture treatment of the two groups was about two hours. In order to examine and distinguish the difference between the two groups, de-qi VAS score was recorded by the volunteers during needle insertion and the electrical resistance by electrical measurement.

The acupuncture needles used in this experiment, including the SCF-N-treated needles and the control stainless steel needles, were produced under the same conditions, in the same factory (Dong Bang acupuncture Inc.), and on the same day, to minimize experimental error.

The process of SCF treatment:. First, the stainless steel chamber and quartz carrier were sterilized using alcohol and autoclaving. Next, the needles were placed on the quartz carrier with the tip pointing upwards and then placed in the chamber and covered. Carbon dioxide was used to remove atmospheric components from the chamber and required volume of ammonia gas was passed. The pressure was increased up to 3000 pound per square inch(psi) and temperature up to 120℃. An hour later, the pressure was relieved and the process of SCF treatment completed. After completion of the treatment, the needles were then randomly selected for material analysis and electrical measurement. Following this, the needles were stored in a vacuum bag. This was done to reduce the influence of atmospheric contaminants on the needles after treatment, resulting in oxidation and rusting. Finally, there would be heterogeneous contact between the inorganic metal and the acupuncture needle. Hence, nitrogen was selected as the main agent for SCF treatment.
Patients in the experimental group received until 12 cycles of FOLFOXIRI plus cetuximab, consisting of a 30-minute infusion of cetuximab first time at a dose of 400 mg per kilogram, after the second time at a dose of 250mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and cetuximab every 14 days until disease progression.
A method of promoting a PTP.zeta. activity promoter or inhibitor, which is useful as a remedy for neutral monoamine nerve system disorder or gastric ulcer caused by Helicobacter pylori or pleiotrophin, by using the physiological functions of PTP.zeta.; and a non-human model animal having a low sensitivity to excitants, pylori toxin or pleiotrophin. A PTP.zeta. activity promoter or inhibitor is screened by administering a test substance  to a PTP.zeta.-knockout mouse and a wild type mouse and comparing and evaluating the PTP.zeta. activities of these animals (for example, occurrenc e of the central monoamine nerve system disorder, the extent of accommodation to new environment, responsiveness to stress, the extent of binding to pylori toxin or pleiotrophin).
The invention provides an intestinal bacterial flora structure improving method and application of the method in preparation of drugs, nutrients, health care products, foods and beverages regulating intestinal flora. A high-throughput sequencing technology and a multivariable statistical method are adopted to find out intestinal bacterial flora closely related to host metabolism. By taking berberine as an example, a novel method for improving an intestinal bacterial flora structure is established. A part of bacteria such as short chain fatty acid producing bacteria can be selectively added, meanwhile a part of bacteria such as endotoxin producing bacteria can be inhibited, and accordingly the metabolism or immune system chaos such as improvement of system inflammatory level, obesity and insulin resistance induced by improper diets is prevented or treated. The invention further provides a method for screening drugs, compounds and foods having similar effects and a composition for improving the intestinal bacterial flora structure. The intestinal bacterial flora structure improving method can be used for development of drugs, nourishments, health-care products, foods, beverages and the like using intestinal bacterial flora as targets.
Prostate cancer is the 7th leading cause of cancer death for men in Taiwan. It is important to identify the extent of disease extent to deliver adequate treatment, either for primary staging or in recurrence. However, conventional imaging techniques including computed tomography, bone scintigraphy, and immunoscintigraphy with 111In-capromab pendetide are not sensitive or specific enough to detect metastatic or recurrent disease. Although more widely applied, magnetic resonance still relies on size and shape criteria. 68Ga-PSMA is a new novel positron emission radiotracer which several preliminary data has shown to be effective of detecting recurrent or metastatic prostate cancer. These studies are confined to a small retrospective European population. In this study we aim to synthesize the novel tracer, find the usefulness of 68Ga-PSMA PET in detecting prostate cancer, including primary staging and recurrence, explore the relationship between imaging and clinical parameters, and seek the possibility of 68Ga-PSMA PET to predict tumor nature and prognosis.
A method for automatically locating microcalcifications indicating breast cancer. The invention assists mammographers in finding very subtle microcalcifications and in recognizing the pattern formed by all the microcalcifications. It also draws attention to microcalcifications that might be overlooked because a more prominent feature draws attention away from an important object. A new filter has been designed to weed out false positives in one of the steps of the method. Previously, iterative selection threshold was used to separate microcalcifications from the spurious signals resulting from texture or other background. A Selective Erosion or Enhancement (SEE) Filter has been invented to improve this step. Since the algorithm detects areas containing potential calcifications on the mammogram, it can be used to determine which areas need be stored at the highest resolution available, while, in addition, the full mammogram can be reduced to an appropriate resolution for the remaining cancer signs.
The study will be performed on Caucasian origin children who are among 2 to 6 years of age. The study group will be composed of children (n=31) who had CMA (Ig E-mediated and/or non-Ig E-mediated and/or mixed type) proved with oral food challenge tests in their early childhood (in ages of 0-2). The inclusion criteria to the study group will be to undergo a Cow's milk elimination (CME) diet or took a hypoallergenic formula in 0-2 years of age for at least 3 months or longer due to CMA allergy and improved afterward, and/or to eliminate other nutrients (e.g., eggs, potatoes, wheat flour, soybean, etc.) other than cow's milk between the ages of 0-2 for at least 3 months or longer, and/or to add these nutrients back to their diet in the last 3 months, and/or not receiving hypoallergenic formula for the last 3 months, not to be on the CME diet at present. Thus, no children in the study and control groups will be on a dietary restriction during the study.
PURPOSE:The titled external preparation having high stability, obtained by adding indomethacin to an aqueous base containing boric acid and or a metal borate, adjusting the blend to a specific pH value. CONSTITUTION:Indomethacin is added to an aqueous base containing boric acid and/or a metal borate, and the blend is adjusted to 4.5-6.5pH, to give an external preparation. Indomethacin is widely used as an nonsteroid anti-inflammatory analgesic, but it is slightly dissolved in water and ordinary mediums, and its stability depends upon selection of base. Since by the use of the base and adjustment of pH the external preparation shows improved stability for a long period, it exhibits stable medicinal effect of indomethacin. An amount of boric acid and/or a metal borate blended in the external preparation is usually 0.05- 5wt%, preferably 0.05-0.5wt%, and a fat and oil component, emulsifying agent, dispersant, gelatinizing agent, etc. usually useful for cosmetic or medicinal external preparation are properly selected depending upon kind of external preparation, etc. and used.
Between baseline and 4-month follow-up, control group patients will receive current standard of care which includes: (a) two or more HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (b) resource referrals from a Patient Navigator based on the participant's needs (e.g., mental health, substance abuse, social support groups, etc.); and (c) automated medical appointment reminders via phone.
In a method for making a dry powder formulation for inhalation, a hydrophilic pharmaceutical compound is processed to remove particles having a diameter of less than about 3 microns. A hydrophilic excipient is similarly processed to remove excipient particles having a diameter of less than about 10 microns. The processed pharmaceutical compound and excipient are optionally separately ripened, by exposure to high humidity. They are then blended together to create the formulation, and ripened again, if desired. The removal of fine particles physically stabilizes the formulation. The formulation accordingly provides a consistent respirable dose, even after exposure to high humidity conditions, for long periods of time, such as when a patient opens the packaging of the pharmaceutical, and then uses it over weeks or months.